LGHT ETF Holdings

Holdings

Symbol	Grade	Price % Change	Allocation
ISRG	B	0.21	14.59
GEHC	D	0.05	9.12
RMD	B	-0.27	7.12
IQV	F	0.49	6.50
DXCM	D	-0.92	5.26
PHG	D	2.23	5.01
VEEV	C	-0.12	4.73
PODD	A	0.78	4.72
BNTX	C	-2.25	3.90
ZBH	C	1.06	3.55
ALGN	F	1.05	2.67
MRNA	F	-2.00	2.38
MASI	A	2.20	2.24
DOCS	A	-1.25	1.67
PRCT	A	5.18	1.35
TNDM	D	2.95	0.60
ALKS	D	0.45	0.60
OMCL	A	-0.33	0.45
EVH	D	-0.43	0.41
IRTC	C	8.53	0.39
PRVA	C	1.21	0.38
LFST	C	-1.47	0.30
TDOC	C	-3.69	0.29
PGNY	F	1.00	0.28
GDRX	F	-5.17	0.27
ALHC	A	2.63	0.20
SDGR	F	1.39	0.19
PHR	F	-0.05	0.15
ACCD	F	-1.56	0.06
TBRG	B	-2.31	0.03
MODV	F	0.62	0.03

Represented by ETF Holdings

Keywords: Medicine Telemedicine S&P 500 Telehealth Nasdaq 100 Diabetes Health Informatics Diabetes Mellitus Endocrine System Endocrinology Glucose Healthcare Providers Life Sciences Medical Equipment Surgery Clinical Medicine Dentist Diabetes Management Disease Drug Discovery

Industries: Health Information Services Health Information Services Medical Devices Medical Instruments & Supplies Biotechnology Diagnostics & Research Healthcare Plans Medical Care Medical Care Facilities

Recent News for Langar Global HealthTech ETF & its Holdings

Date	Stock	Title
Nov 4	MASI	Masimo Q3 2024 Earnings Preview
Nov 4	ALGN	Align Technology Opens 2025 Annual Research Program to Advance Orthodontic and Dental Patient Care
Nov 4	MASI	Here's How Much $1000 Invested In Masimo 10 Years Ago Would Be Worth Today
Nov 4	BNTX	BioNTech Se (BNTX) Q3 2024 Earnings Call Transcript
Nov 4	BNTX	BioNTech Sees Full-Year Revenue at Low End of Guidance; Third-Quarter Results Rise
Nov 4	BNTX	BioNTech SE (BNTX) Q3 2024 Earnings Call Transcript
Nov 4	RMD	Is ResMed (RMD) a Solid Growth Stock? 3 Reasons to Think "Yes"
Nov 4	BNTX	BioNTech Nears A Sell Signal After Cutting Outlook Despite Massive Sales Beat
Nov 4	PODD	Insulet Stock Gains From Expansion Strategies, Innovation
Nov 4	BNTX	BioNTech Variant-adapted COVID-19 Vaccines Do Well In Q3
Nov 4	BNTX	BioNTech Variant-adapted COVID-19 Vaccines Do Well In Q3
Nov 4	RMD	QGEN Stock Set to Gain From FDA's Clearance of QIAstat-Dx Mini Panel
Nov 4	MASI	Exploring Analyst Estimates for Masimo (MASI) Q3 Earnings, Beyond Revenue and EPS
Nov 4	MRNA	Moderna (MRNA) Q3 Earnings on the Horizon: Analysts' Insights on Key Performance Measures
Nov 4	PODD	Stay Ahead of the Game With Insulet (PODD) Q3 Earnings: Wall Street's Insights on Key Metrics
Nov 4	IQV	Interpreting IQVIA (IQV) International Revenue Trends
Nov 4	RMD	BellRing Brands Inc. (BRBR) Hits Fresh High: Is There Still Room to Run?
Nov 4	VEEV	Veeva Systems Inc. (NYSE:VEEV) is largely controlled by institutional shareholders who own 82% of the company
Nov 4	PHG	Philips enrolls first patient in U.S. clinical trial for innovative integrated single-device to treat peripheral artery disease
Nov 4	SDGR	Schrödinger to Present at Jefferies London Healthcare Conference

LGHT targets the global healthcare technology industry. The fund actively invests in HealthTech companies, which the adviser defines as firms that develop technology designed to create healthcare efficiency by addressing key pain points for patients, providers, payors, and hospitals, including those companies that derive a majority of their revenue from HealthTech products and services. The portfolio construction starts by identifying companies that fit into the advisers HealthTech definition. The remaining companies are screened using a proprietary metric that assesses each firms financial health, involvement in relevant controversies, as well as the strength of its team and culture. Each company is then assigned an industry risk score through an algorithm that defines quantitative and qualitative risk categories and weights them accordingly. Finally, each company is reviewed by an investment committee. However, the portfolio manager still has full discretion over the final selection.

ETF Components for LGHT - Langar Global HealthTech ETF